Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02285998 · ClinicalTrials.gov registry record · Phase 3
Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age
A Phase 3 study, sponsored by Protein Sciences Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 9,003
- Enrollment target
NCT02285998 is a Phase 3 study that has completed, run by Protein Sciences Corporation. The registered enrollment target is 9,003 participants.
The verdict
NCT02285998, a Phase 3 study, has completed, sponsored by Protein Sciences Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 9,003 participants
- Enrollment target
Study Summary
The goal of this study is to establish that Flublok Quadrivalent is non-inferior to fully licensed (traditional approval status) quadrivalent inactivated influenza vaccine (IIV4) in protecting against laboratory-confirmed clinical influenza disease in the ≥50 year age population.
Interventions
- BIOLOGICAL Inactivated Influenza Vaccine
- BIOLOGICAL Flublok Quadrivalent Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,003 participants |
| Start Date | 2014-10 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02285998
The ClinicalTrials.gov registry entry for NCT02285998 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 9,003 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Protein Sciences Corporation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Inactivated Influenza Vaccine is the first listed.
NCT02285998 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02285998 about?
NCT02285998 is a clinical study titled "Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age". The goal of this study is to establish that Flublok Quadrivalent is non-inferior to fully licensed (traditional approval status) quadrivalent inactivated influenza vaccine (IIV4) in protecting against laboratory-confirmed clinical influenza disease in the ≥50 year age population.
What is the current status of trial NCT02285998?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 9,003 participants. The study started on 2014-10. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02285998?
The interventions under investigation include: Inactivated Influenza Vaccine (BIOLOGICAL), Flublok Quadrivalent Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02285998?
This trial is sponsored by Protein Sciences Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.